Hepatocellular carcinoma: apatinib after transarterial chemoembolisation prolongs PFS in a Chinese population
Gastrointestinal cancers

Hepatocellular carcinoma: apatinib after transarterial chemoembolisation prolongs PFS in a Chinese population

Positive results in intermediate and advanced disease come after the failure of global trials investigating the combination of TACE with targeted agents 

Read more
Nivolumab plus chemotherapy does not improve PFS in EGFR-mutated NSCLC
Lung and other thoracic tumours

Nivolumab plus chemotherapy does not improve PFS in EGFR-mutated NSCLC

CheckMate 722 trial fails to meet its primary endpoint in patients with cancer progressing on one or two prior lines of EGFR tyrosine-kinase inhibitors 

Read more

Don't miss

  • ESMO Asia Congress Opening ceremony
    2 December 2022, 09:45-11:30 (SGT), Singapore, Hall 406
  • Presidential Symposium
    3 December 2022, 10:45-12:15 (SGT), Singapore, Hall 406

ESMO Asia Congress 2022

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.